Effects of selective COX-2 inhibitors on the gastric permeability of XXXX : a controlled study with placebo and @entity5018 .

@entity1 @entity12698 @entity5018 @entity344 @entity969 @entity3840
OBJECTIVE: Acute and chronic use of non-steroidal anti-inflammatory drugs can increase gastrointestinal permeability. @entity12698 , which selectively inhibits the enzyme @entity3840 , is a novel anti-inflammatory drug with minimal @entity344 effects while retaining anti-inflammatory efficacy. Our aim was to assess the potential effects of @entity12698 on gastric permeability in comparison with placebo and @entity5018 . DESIGN: We conducted a prospective, double-blind, cross-over study. SETTING: This study is carried out at Marmara University Hospital. @entity1 : Twenty-five healthy subjects entered the study but 19 subjects completed the treatment. INTERVENTION: Subjects were randomized to @entity12698 100 mg twice daily, @entity5018 600 mg twice daily or placebo for 7 days in pre-defined sequences. Treatments were separated by a 7 day washout period. MAIN OUTCOME MEASURE: Gastric permeability was assessed by measuring urinary excretion of @entity969 spectrophotometrically. RESULTS: @entity5018 600 mg twice daily produced greater increases in gastric permeability compared with placebo or @entity12698 (geometric mean of urinary @entity969 recovery was 59.15, 32.65 and 33.11 mg/h for @entity5018 , placebo and @entity12698 , respectively) (P < 0.001). @entity12698 was generally better tolerated than @entity5018 . CONCLUSIONS: When compared with @entity5018 , @entity12698 100 mg twice daily has no significant effect on gastric mucosa in healthy subjects.
